The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Open accessAbstract
BACKGROUND: To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals). METHODS: In a double-blind, randomized trial, 102 healthy volunteers were evenly allocated to receive RTS,S/AS01B or RTS,S/AS02A vaccine at months 0, 1, and 2 of the study, followed by malaria challenge. Protected vaccine recipients were rechallenged 5 months later. RESULTS: RTS,S/AS01B and RTS,S/AS02A were well tolerated and were safe. The efficacy of RTS,S/AS01B and RTS,S/AS02A was 50% (95% confidence interval [CI], 32.9%-67.1%) and 32% (95% CI, 17.6%-47.6%), respectively. At the time of initial challenge, the RTS,S/AS01B group had greater circumsporozoite protein (CSP)-specific immune responses, including higher immunoglobulin (Ig) G titers, higher numbers of CSP-specific CD4(+) T cells expressing 2 activation markers (interleukin-2, interferon [IFN]-gamma, tumor necrosis factor-alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group. Protected vaccine recipients had a higher CSP-specific IgG titer (geometric mean titer, 188 vs 73 mug/mL; P < .001), higher numbers of CSP-specific CD4(+) T cells per 10(6) CD4(+) T cells (median, 963 vs 308 CSP-specific CD4(+) T cells/10(6) CD4(+) T cells; P < .001), and higher numbers of ex vivo IFN-gamma ELISPOTs (mean, 212 vs 96 spots/million cells; P < .001). At rechallenge, 4 of 9 vaccine recipients in each group were still completely protected. CONCLUSIONS: The RTS,S/AS01B malaria vaccine warrants comparative field trials with RTS,S/AS02A to determine the best formulation for the protection of children and infants. The association between complete protection and immune responses is a potential tool for further optimization of protection. Trial registration. ClinicalTrials.gov identifier NCT00075049.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W. B., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G., Morris, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1592 · Cited by 1,378
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Self-citationAlonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
Self-citationBojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Self-citationSAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE
Ripley Ballou, W., Hoffman, S. L., Sherwood, J. A., Hollingdale, M. R., Neva, F. A., Hockmeyer, W. T., Gordon, D. M., Schneider, I., Wirtz, R. A., Young, J. F., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90540-x · Cited by 427
Self-citationEfficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Self-citationAlonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67669-6 · Cited by 412
Self-citationGordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1576 · Cited by 327
Self-citationAponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Self-citationInsecticide-treated bednets and curtains for preventing malaria
Lengeler, C. (1998) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd000363 · Cited by 278
Functional signatures of protective antiviral T‐cell immunity in human virus infections
Harari, A., Dutoit, V., Cellerai, C., Bart, P., Du Pasquier, R. A., & Pantaleo, G. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00395.x · Cited by 273
Kester, K. E., McKinney, D. A., Tornieporth, N., Ockenhouse, C. F., Heppner, D. G., Hall, T., Krzych, U., Delchambre, M., Voss, G., Dowler, M. G., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318534 · Cited by 271
Self-citationSun, P., Schwenk, R., White, K., Stoute, J. A., Cohen, J., Ballou, W. R., Voss, G., Kester, K. E., Heppner, D. G., & Krzych, U. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6961 · Cited by 232
Self-citationHEPPNERJR, D., KESTER, K., OCKENHOUSE, C., TORNIEPORTH, N., OFORI, O., LYON, J., STEWART, V, DUBOIS, P., LANAR, D., & KRZYCH, U. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.142 · Cited by 192
Self-citationQS-21: a water-soluble triterpene glycoside adjuvant
Kensil, C. R., & Kammer, R. B. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.9.1475 · Cited by 152
Kester, K. E., Cummings, J. F., Ockenhouse, C. F., Nielsen, R. K., Hall, B. T., Gordon, D. M., Schwenk, R., Krzych, U., Holland, C. A., Richmond, G., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.048 · Cited by 128
Self-citationGarçon, N., Heppner, D. G., & Cohen, J. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.231 · Cited by 118
Self-citationDivision of Labor with a Workforce of One: Challenges in Specifying Effector and Memory T Cell Fate
Reiner, S. L., Sallusto, F., & Lanzavecchia, A. (2007) · Science · doi:10.1126/science.1143775 · Cited by 109
Stewart, V. A., McGrath, S. M., Dubois, P. M., Pau, M. G., Mettens, P., Shott, J. P., Cobb, M., Burge, J. R., LARSON, D. L., Ware, L. A., et al. (2007) · Infection and Immunity · doi:10.1128/iai.01879-06 · Cited by 103
Self-citationStewart, V. A., McGrath, S. M., Walsh, D. S., Davis, S. L., Hess, A. S., Ware, L. A., Kester, K. E., Cummings, J. F., Burge, J. R., Voss, G., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.033 · Cited by 94
Self-citationMettens, P., Dubois, P. M., Demoitié, M., Bayat, B., Donner, M.-N., Bourguignon, P., Stewart, V. A., Heppner, D. G., Garçon, N., & Cohen, J. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.018 · Cited by 81
Self-citationTLR4 agonists as immunomodulatory agents
Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P. (2006) · Journal of Endotoxin Research · doi:10.1179/096805106x118753 · Cited by 80
Wirtz, R. A., Ballou, W. R., Schneider, I., CHEDID, L. A., Gross, M. J., Young, J. F., Hollingdale, M. R., Diggs, C. L., & Hockmeyer, W. T. (1987) · Experimental Parasitology · doi:10.1016/0014-4894(87)90158-5 · Cited by 62
Self-citationStewart, V. A., Walsh, D. S., McGrath, S. M., Kester, K. E., Cummings, J. F., Voss, G., Delchambre, M., Garçon, N., Cohen, J., & Heppner, D. G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.035 · Cited by 31
Self-citationFolena-Wasserman, G., Inacker, R., & Rosenbloom, J. (1987) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)93985-2 · Cited by 24
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Metadata
- Authors
- Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., Juompan, L., Williams, J., Dowler, M., Stewart, V. A., Wirtz, R. A., Dubois, M., Lievens, M., Cohen, J., Ballou, W. R., Heppner, Jr., & RTS, S. V. E. G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 200
- Issue
- 3
- Pages
- 337-346
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2163861382
- Cited by
- 524
- References
- 26
- FWCI
- 32.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.